Member Info for EarlyBird-Rns

26 February 2014 HellermannTyton Group PLC "HellermannTyton" or "the Group" Announcement of refinancing HellermannTyton, the market-leading global manufacturer and provider of high performance and innovative cable management solutions, is pleased to announce that it has signed a new EUR230 million revolving credit facility at Euribor + 1.75% for a term of five years. The new facility replaces the Group's existing EUR220 million senior secured bonds (Euribor +5.125%) and an undrawn EUR80 million revolving credit facility. It is expected that EUR200 million of the new facility will be initially drawn down to repay the bonds with the balance of EUR20 million to be repaid using existing cash reserves. It is anticipated that the bonds will be repaid on 28 March 2014. The one-off costs of refinancing are EUR5 million, which includes the 1% redemption premium paid to the bondholders. Following repayment of the bonds, the new facility will reduce HellermannTyton's interest cost by EUR8 million per annum. HellermannTyton was advised by DC Advisory on the refinancing, and the banking syndicate for the new facility comprises Barclays Bank plc, Commerzbank AG, HSBC Bank plc, Mizuho Bank, Royal Bank of Scotland plc and UniCredit Group, all of whom have taken an equal holding. HellermannTyton will be announcing its preliminary results for the year ended 31 December 2013 on Monday 3 March 2014. Enquiries

26 February 2014 EKF DIAGNOSTICS HOLDINGS PLC ("EKF", the "Company" or the "Group") Final results for the year ended 31 December 2013 EKF Diagnostics Holdings plc (AIM: EKF), the growing in-vitro diagnostics company, announces its audited final results for the year ended 31 December 2013, a year of strong organic growth and improved earnings. EKF has an installed base of c. 50,000 analysers globally and manufactures nearly 50 million tests annually. Financial Highlights -- Revenues up 22% to GBP31.8m (2012: GBP26.1m) - all from organic growth -- Reported EBITDA up 82% to GBP6.7m (2012: GBP3.3m) -- Adjusted EBITDA* up 51% to GBP4.8m (2012: GBP3.2m) -- Cash generated from operations of GBP3.2m (2012: GBP2.5m) -- Cash at 31 December 2013 of GBP2.6m (2012: GBP4.3m) - reflecting deferred consideration payments, investment in additional manufacturing capacity, capitalised development costs and increased working capital due to high December sales * Excluding exceptional items and share based payments Operational Highlights -- Hemo Control / HemoPoint sales up 42% - driven by US growth and significant sales to Mexico -- Quo-Lab and Quo-Test sales up 75% -- Biosen product sales up 20% -- <BETA>HB reagent sales up 8% - despite return of competitor product to the market -- Central laboratory sales (excluding <BETA>HB) rose 26% -- Quo-Lab cartridge automated manufacturing line in Barleben completed -- Establishment of EKF Molecular Diagnostics and launch of seven Research only use PointMan kits -- New products launched and product development pipeline remains strong David Evans, Executive Chairman of EKF, said: "The journey in 2014 promises to be exciting as we underpin the advancements we have made in prior years and seek to capture the opportunities that are in front of us. I truly believe that we are in a golden age for diagnostics and with ever increasing health demands from a growing and ageing population, diagnostics can provide a key role in helping contain costs and at the same time improve overall patient care through disease prevention, early intervention, patient monitoring and ensuring the right patients get the right medicine at the right time. "We continue to look at opportunities to grow our business. 2013 has shown that we have come an extremely long way and now have a well-integrated business. I am confident 2014 will show that we can do even better." Enquiries: EKF Diagnostics Holdings plc Tel: 029 2071 0570 David Evans, Executive Chairman Mob: 07740 084 452 Julian Baines, CEO Mob: 07788 420 859 Paul Foulger, Finance Director Mob: 07710 989 255 Canaccord G

Finally, the Group has strengthened its position in key market segments. Overall, revenues were up 12.9 per cent last year, including the Hume Capital Management business. For the pre-acquisition Group business, whilst overall revenues for the financial year were down 7.4 per cent. on the prior year, revenues recorded in the second half of the year were up 20.3 per cent. against the comparable period in the previous year. Crucially, second half year revenues for the pre-acquisition Group business were up 2.0 per cent. on the first half of this financial year. The trend in revenue growth is clearly improving. The corporate pipeline has improved and we have a number of mandates to execute in 2014 including an IPO and two M&A transactions. This is in addition to the recent new corporate client wins and the sharp increase in secondary fundraising activity. It is particularly pleasing to have been awarded M&A transactions for the first time. Further, asset gathering is picking up momentum, and the wealth management division is close to finalising a number of mandates in the early part of 2014, as well as launching new funds. Post year end the Group has changed its name to Hume Capital Securities plc. This name change is part of the repositioning strategy adopted by the Board last year and reflects the significant changes in the balance of the business that have been made over the past 12 months. The new name aligns the two main aspects of Hume's business, capital markets and wealth management where the focus is on an integrated solution for our clients. This is an important development in the execution of Hume's corporate strategy.

Since our interim statement, where we stated we had achieved an annualised cost reduction of GBP1.2 million per annum, we have now cut costs in total by GBP1.9 million, equating to over GBP700,000 in the second half of the financial year. There is a clear plan in place to reduce costs by a further GBP500,000 per annum, taking the overall annualised saving to GBP2.4 million; this equates to 24.7 per cent. reduction in costs compared to the 2011/12 financial year. As a result of the cost reduction plan, I am pleased to report that the Hume Capital Management businesses have been consistently profitable since June 2013.

26 February 2014 Hume Capital Securities plc ("Hume" or the "Company") Formerly XCAP Securities plc Final results for year ended 31 August 2013 Hume (AIM: HUME) (together with its subsidiaries the "Group"), a financial services group offering full service stockbroking, fund management, corporate advisory and market making services, presents its audited results for the year ended 31 August 2013. -- GBP2.9 million raised of new equity capital to rebuild the capital position of the Company and improve the shareholder base in the financial year, with a further GBP0.9 million raised post year end; -- The Group acquired the Hume Capital Management trading businesses in December 2012, and is pleased to report that these businesses have been consistently profitable since June 2013; -- Revenue increased by 12.9 per cent. to GBP6.0 million (2012: GBP5.3 million); -- Loss before tax reduced to GBP3.7 million (2012: GBP4.5 million); Trading during the first five months of the current financial year has been stronger than the same period last year and the directors believe that the Group's overall financial performance for the year ending 31 August 2014 will show a significant improvement; -- Major cost cutting implemented post acquisition with over GBP1.9 million of annualised costs now taken out of the Group; additional savings of GBP500k per annum implemented post year end; -- Key selective hires have improved our corporate offering; -- Company growth strategy well entrenched with major referral and fund management agreement signed in India since the financial year end; -- Continue to make markets in 288 stocks, including all the clients to which we are retained corporate broker. The Directors' report and financial statements for the year ended 31 August 2013 has been sent to shareholders and uploaded to the Company's website at www.xcapgroup.com. Enquiries: Hume Capital Securities plc Nitin Parekh (Chief Executive Officer) 0203 693 1470 Grant Thornton UK LLP, Nominated Adviser Philip Secrett /Melanie Frean/ Jamie Barklem 020 7383 5100 Chief Executive's Report The financial year under review involved rebuilding the Group against a backdrop of very difficult market conditions. The three priorities were rebuilding the capital position, tackling the inappropriate cost base and strengthening our market position in key business segments. The losses, whilst extremely disappointing, have arisen partly because of the substantial operational changes that needed to be implemented. Overall, the Group made a pre-tax loss of GBP3.7 million, an improvement of GBP0.8 million from the previous year. Part of this loss is attributed to the costs associated with the Hume Capital Management acquisition along with associated re-structuring costs, and in part caused by poor market conditions. Firstly, during the financial year we raised GBP2.9 million of new equity, and

25 February 2014 Omega Diagnostics Group PLC ("Omega" or the "Company") CD4 - Grant of ARIPO Patent Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has just been informed by the Burnet Institute that its exclusively licensed CD4 test for monitoring HIV-positive patients has been awarded a Patent in 15 of the African Regional International Property Organisation ("ARIPO") States. The patent takes effect from 24 July 2013 under number AP 2703. The grant of this patent widens the protection from territories where patents have already been granted in the US, South Africa and the member states of the African Intellectual Property Organisation ("OAPI") and with patents pending in other territories. Contacts:

February 25, 2014 Antrim Updates Fyne Field Development CALGARY, ALBERTA and LONDON, UNITED KINGDOM--(Marketwired - Feb. 25, 2014) - NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. Antrim Energy Inc. (TSX:AEN)(AIM:AEY) ("Antrim" or the "Company") - Antrim Energy Inc., a Canada-based international exploration and production company, is pleased to announce that the UK Department of Energy and Climate Change ("DECC") has agreed to amend the terms of UK Central North Sea Licence P077 Block 21/28a (Antrim 100%) to allow for a Field Development Plan ("FDP") for the Fyne Field to be submitted no later than 31 August 2014. DECC's consent to this amendment includes conditions, amongst other things, that the FDP submission is in its final form, the Environmental Statement is cleared, Antrim is approved as a Production Operator, there is satisfactory evidence of project financing, and reasonable assurance that first production will be achieved prior to 25th November 2016. Antrim previously announced in July 2013 the cooperation on the Fyne Development and signing of a Joint Development Agreement with Enegi Oil Plc ("Enegi") and Advanced Buoy Technology ("ABTechnology") to undertake engineering studies and preparation of an FDP for the Fyne Field. The terms of the agreement include that there will be no costs to the Company prior to FDP approval. During the second half of 2013 Enegi-ABTechnology worked with contractors to engineer the production facility for Fyne. The environmental statement is now due to be submitted during March. Engineering work will continue during the summer with FDP approval prior to 31st August 2014. Upon approval of the FDP by DECC, Enegi-ABTechnology will earn the right to acquire 50% working interest in the licence. Antrim will remain operator. Antrim's CEO Stephen Greer commented, "We are very pleased to have the continued support for DECC with the challenges of developing relatively marginal, stranded oil fields, and the support for new technology to achieve this in the North Sea." Additional information concerning Antrim Energy Inc. is available at www.antrimenergy.com. Investor inquiries may be directed to info@antrimenergy.com or 1-403-264-5111. Forward-Looking and Cautionary Statements This press release and any documents incorporated by reference herein contain certain forward-looking statements, including statements regarding Antrim's future business plans, which are based on Antrim's internal reasonable expectations, estimates, projections, assumptions and beliefs as at the date of such statements. Forward-looking statements often, but not always, are identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "targeting",

Artilium plc ("Artilium" or the "Company") Mobile World Congress Artilium plc (AIM: ARTA), the AIM quoted telecom software and solutions provider,is exhibiting its newly released 8.9 software at Mobile World Congress in Barcelona. This new version of the realtime Authentication, Authorization and Accounting software brings increased functionalities and flexibilities for Mobile Operators. For further information, please visit the Company's website (www.artilium.com) or contact: Artilium Plc +32 (0)50230300

24 February 2014 ECO Animal Health Group plc (AIM: EAH) ECO RECEIVES FIRST MARKETING AUTHORISATION FOR AIVLOSIN® IN THE REPUBLIC OF KOREA ECO is pleased to announce that it has received a marketing authorisation for Aivlosin® 42.5 mg/g premix for swine from the Animal and Plant Quarantine Agency of the Republic of Korea. The product will be marketed for the treatment of swine respiratory disease caused by Mycoplasma hyopneumoniae underECO's Valosin® trade name in this territory. ECO has a long standing relationship with a South Korean distributor who assisted in obtaining this marketing authorisation. Launch plans are well advanced and is expected to take place within a couple of months. Pork production is the largest agricultural sector after rice in South Korea, which produces almost one million metric tons of pork every year, with consumption increasing faster than any other type of meat. Aivlosin®, ECO's patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry. Peter Lawrence, Chairman of ECO, commented "This authorisation in the Republic of Korea is another encouraging and positive step in the development of Aivlosin® as a fast growing, truly global brand. It underlines ECO's continued commitment to being a major force in the international market for veterinary pharmaceutical products." Contacts: ECO Animal Health Group plc Marc Loomes 020 8447 8899 Spiro Financial Anthony Spiro 020 8336 6196 Cenkos Securities plc Stephen Keys 020 7397 8926 (Nominated Adviser) ECO Animal Health Gr

24 February 2014 Tricor plc ("Tricor" or the "Company") Trading Update Tricor (AIM: TRIC), the investment company focussed on the resources sector with investments in iron sand and sand trading operations in the Philippines, has been advised by Tricor Minerals Pte Ltd ("TM"), which is 72 per cent. owned by Tricor, that production at its iron sand plant has been significantly below its expected production capacity. TM believes this could be due to design flaws in the plant and is therefore in the process of engaging consultants to investigate. As such, it has stopped iron sand production for the time being. At this time, it is not known when the plant will be in production again. Separately, Tricor Environmental Pte Ltd ("TEPL"), 100% owned by Tricor, has informed the Company that it has sold 319,353 metric tonnes and 345,541 metric tonnes of sand in the months of December 2013 and January 2014 respectively, in line with its expectations. TEPL will continue to increase its sand operations as fast as it can. Enquiries: Tricor plc Chan Fook Meng Chairman/CEO +65 62362985 Allenby Capital Ltd (Nominated Adviser & Joint Broker) Jeremy Porter Nick Naylor James Reeve +44 (0) 20 3328 5656 XCAP Securities plc (Joint Broker) Jon Belliss Adrian Kirk +44 (0) 20 7101 7070 Blythe Weigh Communications Paul Weigh Halimah Hussain +44 (0) 20 7138 3204 This information is pr

Straight PLC 17 February 2014 Statement re: rise in Straight's share price - Correction The following amendment has been made to the 'Statement re: rise in Straight's share price' released on 14 February 2014 at 15:49 hrs under RNS No 1550A. In the announcement released on 14 February 2014 incorrectly stated the relevant deadline, which should have been 14 March 2014. All other details remain unchanged. The full amended text is shown below. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION This is an announcement falling under Rule 2.4 of the Takeover Code and does not constitute an announcement of a firm intention to make an offer under Rule 2.7 of the Takeover Code. There can be no certainty that an offer will be made nor as to the terms on which any offer might be made. 14 February 2014 Straight plc

Certainly moving in the right direction:) GLA!

About to have an upwards tick again:)

Showing as sells...

We'll see a .90 - 92p close today... The Rns was not too bad and the market simply had a knee jerk reaction... Only time will tell?:) GLA

About to tick upwards again:)

'was not that poor'

The Rns was that poor nor did it warrant the drop in share price... GLA

14 February 2014 Top Level Domain Holdings Limited ("TLDH", the "Company" or "Group") .LONDON update The Directors of Top Level Domain Holdings Limited (AIM:TLDH.L) are delighted to announce that its client, Dot London Domains Ltd ("Dot London"), has today announced that .LONDON will begin taking registrations on 29 April 2014 marking the formal launch of the .LONDON domain. Separately, based on YouGov research commissioned by London & Partners, the Mayor's official promotional organisation for London, Dot London projects that over a quarter of London's 840,000 small businesses are likely to apply for an address in the .LONDON domain. Leading brands and international organisations have also already expressed their desire to secure .LONDON addresses according to the Dot London announcement. As part of the launch programme, London based businesses and Londoners will be given an initial three-month priority period in which to pre-register domain names. During the same period, trademark holders registered in ICANN's Trademark Clearinghouse, will also be able to submit a claim for their associated address(es) for their trademark. London will be one of the first cities in the world to introduce its own top level domain. A copy of the Dot London's full announcement can be viewed at http://www.londonandpartners.com/media-centre/. Further Information:

Hey Dude.... A bit hungover today. It's hard work here in Thailand!